IBI3032

DRUG3 trials

Sponsors

Fortvita Biologics (USA)Inc., Innovent Biologics Technology Limited (Shanghai R&D Center)

Conditions

HealthyOverweight or Obesity

Early Phase 1

A Study of IBI3032 in Chinese Healthy Subjects

CompletedNCT07134127

Innovent Biologics Technology Limited (Shanghai R&D Center)Healthy

Start: 2025-08-29End: 2025-10-07Updated: 2025-11-17

Phase 1

A Study of IBI3032 in Healthy Participants

RecruitingNCT07120425

Fortvita Biologics (USA)Inc.Healthy

Start: 2025-09-10End: 2025-11-13Target: 32Updated: 2025-09-17

A Study of IBI3032 in Chinese Participants With Overweight or Obesity

Active, not recruitingNCT07170319

Innovent Biologics Technology Limited (Shanghai R&D Center)Overweight or Obesity

Start: 2025-09-25End: 2026-03-31Updated: 2025-12-31

Related Papers

1690-P: Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IBI3032, a Novel Oral Nonpeptide GLP-1 Receptor Agonist: Single- and Multiple-Ascending Dose Studies in Chinese Adults

Diabetes2026-06-05